1h Free Analyst Time
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Metabotropic Glutamate Receptor 2 - Drugs In Development, 2022, outlays comprehensive information on the Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.Speak directly to the analyst to clarify any post sales queries you may have.
Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Metabotropic glutamate receptor 2 is a protein encoded by the GRM2 gene. It is a receptor for glutamate. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling inhibits adenylate cyclase activity. May mediate suppression of neurotransmission or may be involved in synaptogenesis or synaptic stabilization. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 4, 5 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Schizophrenia, Depression, Treatment Resistant Depression, Anxiety Disorders, Drug Addiction, Major Depressive Disorder, Alzheimer's Disease, Mild Cognitive Impairment, Nicotine Addiction, Panic Disorders, Parkinson's Disease, Partial Seizure, Post-Traumatic Stress Disorder (PTSD), Psychosis and Unspecified Neurologic Disorders.
Furthermore, this report also reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)
- The report reviews Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
- Introduction
- Report Coverage
- Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Overview
- Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Companies Involved in Therapeutics Development
- Addex Therapeutics Ltd
- Bristol-Myers Squibb Co
- Camino Pharma LLC
- Denovo Biopharma LLC
- Eli Lilly and Co
- Johnson & Johnson
- Merck & Co Inc
- Noema Pharma AG
- Sumitomo Pharma Co Ltd
- Taisho Pharmaceutical Holdings Co Ltd
- Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Drug Profiles
- BMT-133218 - Drug Profile
- Product Description
- Mechanism Of Action
- DSP-3456 - Drug Profile
- Product Description
- Mechanism Of Action
- JNJ-1813 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- LY-3020371 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- mGlu2 NAM - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- NOE-109 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- pomaglumetad methionil - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SBP-0069330 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- SBP-9881 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Small Molecule to Agonize Metabotropic Glutamate Receptor 2 for Psychosis - Drug Profile
- Product Description
- Mechanism Of Action
- Small Molecules to Antagonize mGlu2 for Anxiety and Depression - Drug Profile
- Product Description
- Mechanism Of Action
- TS-134 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- TS-161 - Drug Profile
- Product Description
- Mechanism Of Action
- History of Events
- Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Dormant Products
- Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Discontinued Products
- Metabotropic Glutamate Receptor 2 (GPRC1B or MGLUR2 or GRM2) - Product Development Milestones
- Featured News & Press Releases
- Nov 15, 2021: Addex strategic partner successfully completes Phase 1 in Japan with ADX71149
- Aug 25, 2021: Camino Pharma initiates phase 1 study of SBP-9330 in development for the treatment of tobacco use disorder
- Jul 01, 2021: Addex, Stanford University and University of Copenhagen Publish mGlu2 Structure in Nature Using Addex Allosteric Modulators
- Jun 07, 2021: Addex starts phase 2 clinical study of ADX71149 for epilepsy
- Jan 21, 2021: Addex ADX71149 receives IND approval to start a phase 2a clinical study in epilepsy
- Sep 16, 2020: $11.4 million NIH grant advances drug to treat nicotine addiction
- Jun 30, 2020: Camino Pharma receives $920K Small Business Innovation Research (SBIR) grant from the National Institute of Mental Health
- Jun 16, 2020: Addex mGlu2 PAM program to advance into Epilepsy Phase 2a proof of concept clinical study
- Oct 02, 2018: Addex selective mGlu2 PAM ADX71149 included in review highlighting promising investigative drugs for epilepsy
- Sep 04, 2018: Addex’s selective mGlu2 PAM ADX71149 shows promise in treating severe panic disorders and PTSD
- Feb 27, 2017: Addex's ADX71149 Anti-Epileptic Effect Highlighted in Scientific Journal, Epilepsia
- Sep 23, 2015: Addex ADX71149 Demonstrates Synergistic Efficacy with Levetiracetam in Preclinical Models of Epilepsy
- Feb 07, 2014: Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder with Significant Anxiety Symptoms
- Oct 29, 2013: Addex Licensee Completes Enrolment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression
- Nov 05, 2012: Addex Reports Top-line Data From Successful Phase IIa Clinical Study With ADX71149 In Schizophrenia Patients
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact the Publisher
- Disclaimer
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Therapy Areas, 2022
- Number of Products under Development by Indication, 2022
- Number of Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products under Investigation by Universities/Institutes, 2022
- Products under Investigation by Universities/Institutes, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
- Pipeline by Addex Therapeutics Ltd, 2022
- Pipeline by Bristol-Myers Squibb Co, 2022
- Pipeline by Camino Pharma LLC, 2022
- Pipeline by Denovo Biopharma LLC, 2022
- Pipeline by Eli Lilly and Co, 2022
- Pipeline by Johnson & Johnson, 2022
- Pipeline by Merck & Co Inc, 2022
- Pipeline by Noema Pharma AG, 2022
- Pipeline by Sumitomo Pharma Co Ltd, 2022
- Pipeline by Taisho Pharmaceutical Holdings Co Ltd, 2022
- Dormant Products, 2022
- Discontinued Products, 2022
- Number of Products under Development by Stage of Development, 2022
- Number of Products under Development by Top 10 Indications, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Addex Therapeutics Ltd
- Bristol-Myers Squibb Co
- Camino Pharma LLC
- Denovo Biopharma LLC
- Eli Lilly and Co
- Johnson & Johnson
- Merck & Co Inc
- Noema Pharma AG
- Sumitomo Pharma Co Ltd
- Taisho Pharmaceutical Holdings Co Ltd
